Skip to main content

Table 2 Generalized estimating equation (GEE) models to evaluate the effects of Levothyroxine replacement therapy (LRT) on inflammatory, oxidative stress, hemoglobin, and lipid profile parameters of hypothyroid patients

From: Improvement of blood inflammatory marker levels in patients with hypothyroidism under levothyroxine treatment

Parameters Pre-treatment Six months Twelve months Wald Chi-square df P-value
Mean (95 % CI) Mean (95 % CI) Mean (95 % CI)
TSH (μIU/mL) 32.4 (18.0–30.4) 20.7 (8.6–49.8) 10.5 (6.3–17.4) 18.496 2 <0.0001
FT4 (ng/dL) 0.8 (0.7–0.9) 3.4 (1.8–6.6) 2.7 (1.3–5.8) 33.684 2 <0.0001
IL-10 (pg/mL) 132.7 (124.5–141.0) 160.7 (150.7–170.6) 184.6 (174.8–194.4) 181.076 2 <0.0001
IL-1 (pg/mL) 73.0 (68.5–77.4) 57.9 (52.6–63.1) 45.0 (40.4–49.6) 321.214 2 <0.0001
IL-6 (pg/mL) 90.1 (83.7–96.4) 70.5 (63.9–77.1) 49.9 (44.1–55.6) 512.104 2 <0.0001
INF-γ (pg/mL) 144.8 (141.0–148.6) 98.6 (93.1–104.5) 80.0 (75.8–84.3) 386.001 2 <0.0001
TNF-α (pg/mL) 122.8 (120.5–125.1) 90.4 (86.8–94.0) 66.2 (61.6–71.1) 341.402 2 <0.0001
hs-CRP (mg/dl) 0.6 (0.3–1.1) 0.5 (0.3–0.8) 0.9 (0.5–1.7) 2.519 2 0.284
NP-SH (nmol NP - SH/mL erit) 1522.4 (1374.9–1670.0) 1098.1 (929.3–1267.0) 1004.6 (757.5–1251.7) 23.528 2 <0.0001
Total-SH (nmol T -SH/ml plasma) 823.3 (683.5–963.2) 624.0 (537.1–710.8) 660.5 (584.2–772.8) 5.388 2 0.068
δ-ALA-D (nmol PBG/hour/ml of blood) 3.6 (2.7–4.4) 3.1 (1.9–4.3) 3.0 (2.1–4.0) 0.644 2 0.725
TBARS (nmol MDA/mL erit) 5.3 (4.0–6.7) 7.2 (4.8–8.5) 6.7 (4.8–8.5) 2.862 2 0.239
Hemoglobin (g/dL) 13.1 (12.6–13.6) 13.4 (13.0–13.9) 13.6 (13.2–14.0) 8.252 2 0.016
TC (mg/dL) 201.5 (176.7–244.2) 198.4 (168.5–228.4) 198.4 (171.9–225.0) 1.567 2 0.457
HDL- C (mg/dL) 54.3 (48.8–59.7) 50.9 (41.8–60.0) 52.1 (45.8–58.4) 0.670 2 0.715
LDL- C (mg/dL) 124.2 (102.6–150.5) 115.5 995.5–139.7) 115.5 (99.0–134.7) 2.146 2 0.342
TG (mg/dL) 117.5 (88.1–156.9) 139.2 (99.2–195.4) 119.6 (85.3–167.7) 1.085 2 0.581
  1. df = degrees of freedom; adjusted for overt hypothyroidism and subclinical hypothyroidism